S Morteza Seyed Jafari,Gemma Caro,Shari R Lipner et al.
S Morteza Seyed Jafari et al.
Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have transformed the treatment of type II diabetes and obesity. Since their introduction, studies continue to reveal their beneficial effects in a range of other conditions. However, hair...
Acute and Chronic Cutaneous Graft-versus-Host Disease: Diagnosis, Treatment, and Emerging Directions [0.03%]
Connie R Shi,Mihir K Patil,Grant J Riew et al.
Connie R Shi et al.
Cutaneous graft-versus-host disease (GVHD) is a frequent manifestation after allogeneic hematopoietic stem cell transplantation. This review synthesizes classification, pathophysiology, risk factors, and diagnostic frameworks for acute and ...
Luca Valtellini,Gabriele Perego,Italo Francesco Aromolo et al.
Luca Valtellini et al.
Dissecting cellulitis of the scalp is a rare, primary neutrophilic cicatricial alopecia that manifests with painful nodules, abscesses, and interconnected sinus tracts. It predominantly affects young adult men and frequently coexists with o...
Emerging Therapeutic Strategies in Cutaneous T-Cell Lymphoma: A Comprehensive Review of Clinical Trials [0.03%]
皮病T细胞淋巴瘤治疗策略的临床研究综合述评
Yoni Sacknovitz,Rachel Ma,Christina M Bear et al.
Yoni Sacknovitz et al.
Background: Cutaneous T-cell lymphomas (CTCL), including mycosis fungoides (MF) and Sézary syndrome (SS), are rare non-Hodgkin lymphomas characterized by skin-homing malignant T cells. While early-stage disease carries f...
Long-Term Efficacy and Safety of Ritlecitinib in Adults and Adolescents with Alopecia Areata: 3-Year Results from the ALLEGRO Phase 2b/3 and ALLEGRO-LT Phase 3 Clinical Studies [0.03%]
长期评价利特西替尼治疗斑秃成人和青少年患者的疗效和安全性：ALLEGRO II期b/III期和ALLEGRO-LT III期临床研究的3年结果
Maryanne Senna,Jennifer Soung,Ignasi Figueras et al.
Maryanne Senna et al.
Background/objective: Ritlecitinib, an oral JAK3/TEC family kinase inhibitor, demonstrated efficacy over 48 weeks in patients aged ≥ 12 years with alopecia areata (AA) in the ALLEGRO phase 2b/3 study and initial extensio...
Corrective and Restorative Dermatology in Cancer Survivors: An Urgent Unmet Need! [0.03%]
肿瘤幸存者的纠正性皮肤修复治疗：一个亟待解决的迫切需求！
Luca Rapparini,Timila Assia Touhouche,Davide Fattore et al.
Luca Rapparini et al.
The increasing efficacy of oncological therapies has led to a rapidly growing population of cancer survivors, shifting clinical attention from acute treatment-related toxicities to long-term and late sequelae. Among these, dermatological se...
Safety and Efficacy of Treatment with Dupilumab for up to 2 Years in Infants and Young Children with Atopic Dermatitis [0.03%]
dupilumab治疗婴幼儿期至学龄前中重度特应性皮炎长达2年的疗效和安全性
Amy S Paller,Eric L Simpson,Elaine C Siegfried et al.
Amy S Paller et al.
Background: Atopic dermatitis (AD) is a chronic inflammatory disease with a high clinical burden and risk of persistence in pediatric patients. Objective:...
Psychocutaneous Disorders in Pediatric and Adolescent Populations: A Narrative Review [0.03%]
儿科和青少年人群中的心理皮肤病学障碍：叙述性综述
Isabella J Tan,Alexis Mitelman,Mohammad Jafferany
Isabella J Tan
Psychocutaneous disorders (PCDs) in children and adolescents lie at the intersection of dermatology and psychiatry and include primary psychiatric conditions with cutaneous manifestations, dermatologic diseases with psychiatric sequelae, an...
Ritlecitinib for Severe Alopecia Areata: A 24-Week, Multicentre, Real-World Study [0.03%]
有关重度斑秃的一项为期24周的多中心真实世界研究：利特昔替尼的效果如何？
Michela Starace,Luca Rapparini,Francesca Pampaloni et al.
Michela Starace et al.
Background: Ritlecitinib, an oral selective inhibitor of Janus kinase 3 and the TEC family of kinases, has recently been approved for the treatment of severe alopecia areata, but real-world data are still limited. ...
Jaime Piquero-Casals,Clémence Bertold,Agustín Alomar et al.
Jaime Piquero-Casals et al.
Background: Vitiligo is a multi-factorial autoimmune skin disorder often triggered by environmental exposures. Although the exposome has gained attention, no systematic review has fully assessed its role in vitiligo. ...